Please assess the completion status of the following clinical trial:

Trial Title: Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. In the opinion of the treating physician, treatment with one of the following regimens should represent an appropriate treatment for the patient.~   - Capecitabine 825 mg/m2 BID days 1 - 14 q 3 weeks~2. Patients should have a histologically or cytologically confirmed diagnosis of colorectal cancer.~3. Patients must have received at least one but no more than two prior chemotherapy regimen(s) for the treatment of metastatic or recurrent disease.~4. ECOG performance status 0 or 1.~   * Leukocytes \>= 4,000/μL~  * absolute neutrophil count \>= 1,500/ μL~  * platelets \>= 100,000/ μL~  * HCT \> 28% (with or without growth factor support)~  * Creatinine \<= 2.5 mg/dl~  * total bilirubin \< 1.5 x upper limit of normal~  * transaminase \< 2.5 x upper limit of normal~5. Patients must have recovered from acute toxicity-excluding alopecia-related to prior therapy, including surgery or radiotherapy.~6. Patients with brain metastases may be admitted, provided the disease has been treated and been stable for 2 months.~7. Patients must have ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~1. Patients receiving any other investigational agents or devices.~2. History of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine).~3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, psychiatric illness, or social situations that would limit compliance with study requirements.~4. HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study due to potential pharmacokinetic interactions with perifosine.~5. Patients with a history of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within 6 months of enrollment), or New York Heart Assoc. class II - IV congestive heart failure.~6. Female patients who are pregnant or lactating are ineligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Perifosine + Capecitabine (Type: EXPERIMENTAL): Perifosine 50 mg/d qd + Capecitabine 825 mg/m\^2 BID days 1 - 14 q 3 weeks until progression
- Arm 2: Perifosine Placebo + Capecitabine (Type: PLACEBO_COMPARATOR): Perifosine Placebo 50 mg/d qd + Capecitabine 825 mg/m\^2 BID days 1 - 14 q 3 weeks until progression

Based on this trial design, predict the completion outcome and termination type (if applicable).